Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Dynamk Capital

Founders Daniella Kranjac

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 21
Average round size
info
The average size of a deal this fund participated in
$10M
Portfolio companies 12
Rounds per year 3.50
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Exits 1
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Life Science
  • Manufacturing
Summary

Dynamk Capital is the famous VC, which was founded in 2016. The venture was found in North America in United States. The leading representative office of defined VC is situated in the New York.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Dynamk Capital, startups are often financed by Ventry Industries, The Thiel Foundation, National Institutes of Health. The meaningful sponsors for the fund in investment in the same round are Vanedge Capital, Third Kind Venture Capital, SV Angel. In the next rounds fund is usually obtained by Vanedge Capital, National Institutes of Health, Madrona Venture Group.

The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Chemical, Biotechnology. Among the various public portfolio startups of the fund, we may underline Envisagenics, Flodesign Sonics, RoosterBio

The increased amount of exits for fund were in 2019. The important activity for fund was in 2019. Comparing to the other companies, this Dynamk Capital performs on 9 percentage points less the average number of lead investments. Deals in the range of 5 - 10 millions dollars are the general things for fund. The real fund results show that this VC is 80 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.

The fund was created by Daniella Kranjac. We also calculated 3 valuable employees in our database.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AGTech Holdings China, Hong Kong, Hong Kong Island
BPI Capital Partners New York, New York, United States
Brockhaus Private Equity Frankfurt, Germany, Hessen
Curious Office Partners Seattle, United States, Washington
Enphase Energy California, Petaluma, United States
Ernst & Young England, London, United Kingdom
K-Svets Venture Sweden, Vastra Gotaland, Västra Götaland County
Knoll Capital Management -
Launch Africa Ebène, Mauritius, Plaines Wilhems
Leerink Transformation Partners Boston, Massachusetts, United States
Linden Capital Berlin, Berlin, Germany
MESA New York, New York, United States
O2h Ventures -
REAL WORLD Japan, Kanagawa Prefecture, Kawasaki
Riverbed Technology California, San Francisco, United States
Sandler Capital New York, New York, United States
Shenzhen Aoto Electronics China, Guangdong, Tianjin
SSC Fund Beijing, Beijing, China
Toyota Tunas -
UCAL Fuel Systems Chennai, India, Tamil Nadu

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

CellFE

Biotechnology
Health Care
$22M27 Sep 2023 California, United States

Lucid Scientific

Biotechnology
Medical
Product Research
$7M05 Sep 2023 Atlanta, Georgia, United States

Vernal Biosciences

$20M27 Jun 2023 Burlington, Vermont, United States

Vernal Biosciences

$21M02 Jun 2022 Burlington, Vermont, United States

Bionter

Health Care
Pharmaceutical
$3M27 Apr 2022 Riehen, Basel-Stadt, Switzerland

Xcell Biosciences

Biotechnology
Health Diagnostics
Manufacturing
Medical
Therapeutics
$27M19 Jan 2022 San Francisco, California, United States

Curi Bio

Biopharma
Medical
$10M29 Dec 2021 Seattle, Washington, United States

Virica Biotech

Biotechnology
04 Oct 2021 Ottawa, Ontario, Canada

Envisagenics

Artificial Intelligence
Bioinformatics
Biotechnology
Machine Learning
Therapeutics
$19M29 Sep 2021 New York, New York, United States
News
Mouse brains and more in 3D: Seattle microscopy startup lands $4M to visualize medical specimens

– Lightspeed Microscopy, a Seattle startup, raised $4m in a Series A financing round.
– The round was led by Dynamk Capital and joined by other investors.
– The company is developing an end-to-end microscopy system for pathologists.
– The platform adapts a type of microscopy commonly used for basic research to assess pathology specimens in three dimensions.

Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms

– Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms
– The round was led by Dynamk Capital
– The investment will be used to scale its existing business and accelerate the development of new innovative human stem cell platforms, including its MantarrayTM platform.
– With this financing round, Curi Bio is welcoming Dr. Gustavo Mahler, Managing Partner at Dynamk Capital, as a new board member.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Dynamk Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 21
Average round size 10M
Rounds per year 3.50
Peak activity year 2021
Lead investments 6
Follow on index 0.43
Exits 1
Group Appearance index 0.57

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

CellFE

Biotechnology
Health Care
$22M27 Sep 2023 California, United States

Lucid Scientific

Biotechnology
Medical
Product Research
$7M05 Sep 2023 Atlanta, Georgia, United States

Vernal Biosciences

$20M27 Jun 2023 Burlington, Vermont, United States

Vernal Biosciences

$21M02 Jun 2022 Burlington, Vermont, United States

Bionter

Health Care
Pharmaceutical
$3M27 Apr 2022 Riehen, Basel-Stadt, Switzerland

Xcell Biosciences

Biotechnology
Health Diagnostics
Manufacturing
Medical
Therapeutics
$27M19 Jan 2022 San Francisco, California, United States

Curi Bio

Biopharma
Medical
$10M29 Dec 2021 Seattle, Washington, United States

Virica Biotech

Biotechnology
04 Oct 2021 Ottawa, Ontario, Canada

Envisagenics

Artificial Intelligence
Bioinformatics
Biotechnology
Machine Learning
Therapeutics
$19M29 Sep 2021 New York, New York, United States
Crunchbase icon

Content report

The following text will be sent to our editors: